Keywords: degralix, shows, promise, prostate, cancer, switzerland, ferring

Degralix shows promise for prostate cancer

Article | 17 April 2006

Switzerland's Ferring Pharmaceuticals has announced positive data from Phase IIb trials of Degarelix, a peptide gonadotrophin receptor antagonist, used in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Ferring Pharmaceuticals

Go to company listing

Related Drugs

Striant

Testosterone

Testoderm

Go to drug listing